Efficacy of Single Dose Intravenous Ondansetron vs Metoclopramide in Children with Acute Gastroenteritis with Vomiting
Abstract
Objective: To compare the efficacy of ondansetron and metoclopramide in children with gastroenteritis with vomiting. Study Design: cross-sectional study Place and Duration of Study: This study was conducted at the Pediatric Unit, Lady Reading Hospital Peshawar from May, 2019 to November, 2019. Materials and Methods: A total of 112 cases were enrolled and two groups made. Children in group A were treated with rehydration therapy and metoclopramide for vomiting whereas children in group B were treated with rehydration therapy plus ondansetron. Patients were monitored for vomiting at one and 06 hours of administration of antiemetic drugs. Results: Of the total 112 cases, 66 (58.9 %) were male, 46 (41.1 %) were female patients. Mean age was 3.45 ± 1.70 years. Mean BMI was 22.32 ± 1.13 kg/m2 while 15 (13.4 %) of cases were obese. History of breastfeeding was noted in 73 (65.2%). Mean duration of illness was 4.24 ± 2.15 days, 106(64.6%) had a total duration of 7 days. Of total cases 81 (72.3 %) were vaccinated, 31 (27.7 %) unvaccinated. Out of 112 cases, 100 responded well to treatment, in Group A the efficacy was 46 (82.1%) whereas in group B it was 54 (96.4%) Conclusion: Ondansetron was found to be safe, efficacious, for treating children with acute gastroenteritis with vomiting. And having a higher efficacy than metoclopramide, hence it is concluded that ondansetron can be safely given to children with acute gastroenteritis with vomiting
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.